BioCryst Pharma (BCRX) Misses Q1 EPS by 8c
Get Alerts BCRX Hot Sheet
Price: $4.41 -0.45%
Revenue Growth %: +26.2%
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
SFST, VLTO, CLIR, More
Revenue Growth %: +26.2%
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.31), $0.08 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $4.82 million versus the consensus estimate of $5.42 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Hexcel Corp. (HXL) Tops Q1 EPS by 2c, Offers Guidance
- Nucor (NUE) Misses Q1 EPS by 21c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!